Flavin-containing monooxygenase 3 gene polymorphisms in Turkish population

Toxicology Mechanisms and Methods

Volumn 22, Issue 6, 2012, Pages 461-465

  Özhan, Gül ^a   Topal, Pinar ^a   Alpertunga, Buket ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Flavin containing monooxygenase 3; FMO3; Genotype frequency; Haplotype frequency; SNPs

Indexed keywords

DIMETHYLANILINE MONOOXYGENASE; FLAVIN CONTAINING MONOOXYGENASE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; FEMALE; FMO 3 GENE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TURKEY (REPUBLIC);

ALLELES; BASE SEQUENCE; DNA PRIMERS; HAPLOTYPES; HUMANS; OXYGENASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; TURKEY;

EID: 84862267737     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2012.672481     Document Type: Article

References (30)

1. Cashman JR. 2004. The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discov Today 9:574-581. (Pubitemid 38760181)
2. Cashman JR, Zhang J. 2002. Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. Drug Metab Dispos 30:1043-1052.
3. Cashman JR, Zhang J. 2006. Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 46:65-100. (Pubitemid 43271184)
4. Cashman JR, Zhang J, Leushner J, Braun A. 2001. Population distribution of human flavin-containing mono-oxygenase form 3: gene polymorphisms. Drug Metab Dispos 29:1629-1637. (Pubitemid 33111596)
5. Daly AK, Steen VM, Fairbrother KS, Idle JR. 1996. CYP2D6 multiallelism. Meth Enzymol 272:199-210. (Pubitemid 26299883)
6. Dolphin CT, Riley JH, Smith RL, Shephard EA, Phillips IR. 1997. Structural organization of the human flavin-containing monooxygenase 3 gene (FMO3), the favored candidate for fish-odor syndrome, determined directly from genomic DNA. Genomics 46:260-267. (Pubitemid 28013422)
7. Hao DC, Sun J, Furnes B, Schlenk D, Hou ZF, Zhang YP, Yang SL, Yang L. 2006. Haplotype frequency distribution and linkage disequilibrium analysis of single nucleotide polymorphisms at the human FMO3 gene locus. Biochem Genet 44: 391-407.
8. Hao D, Sun J, Furnes B, Schlenk D, Li M, Yang S, Yang L. 2007. Allele and genotype frequencies of polymorphic FMO3 gene in two genetically distinct populations. Cell Biochem Funct 25:443-453. (Pubitemid 47066722)
9. Hernandez D, Addou S, Lee D, Orengo C, Shephard EA, Phillips IR. 2003. Trimethylaminuria and a human FMO3 mutation database. Hum Mutat 22:209-213. (Pubitemid 37071637)
10. Hernandez D, Janmohamed A, Chandan P, Phillips IR, Shephard EA. 2004. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 14:117-130. (Pubitemid 38253647)
11. Hisamuddin IM, Wehbi MA, Chao A, Wyre HW, Hylind LM, Giardiello FM, Yang VW. 2004. Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res 10:8357-8362. (Pubitemid 40053397)
12. Kang JH, Chung WG, Lee KH, Park CS, Kang JS, Shin IC, Roh HK, Dong MS, Baek HM, Cha YN. 2000. Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FM03 gene mutations in a Korean population. Pharmacogenetics 10:67-78.
13. Koukouritaki SB, Hines RN. 2005. Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development. Pharmacogenomics 6:807-822. (Pubitemid 41724355)
14. Koukouritaki SB, Poch MT, Henderson MC, Siddens LK, Krueger SK, VanDyke JE, Williams DE, Pajewski NM, Wang T, Hines RN. 2007. Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants. J Pharmacol Exp Ther 320:266-273. (Pubitemid 46028481)
15. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. 2002. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 51:236-243. (Pubitemid 34101340)
16. Krueger SK, Williams DE. 2005. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 106:357-387. (Pubitemid 40726294)
17. Lambert DM, Mamer OA, Akerman BR, Choinière L, Gaudet D, Hamet P, Treacy EP. 2001. In vivo variability of TMA oxidation is partially mediated by polymorphisms of the FMO3 gene. Mol Genet Metab 73:224-229. (Pubitemid 32709612)
18. Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, Cashman JR. 2003. Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies. Drug Metab Dispos 31:854-860. (Pubitemid 36759054)
19. Lomri N, Gu Q, Cashman JR. 1992. Molecular cloning of the flavin-containing monooxygenase (form II) cDNA from adult human liver. Proc Natl Acad Sci USA 89:1685-1689.
20. Mayatepek E, Flock B, Zschocke J. 2004. Benzydamine metabolism in vivo is impaired in patients with deficiency of flavin-containing monooxygenase 3. Pharmacogenetics 14:775-777. (Pubitemid 39552793)
21. Overby LH, Carver GC, Philpot RM. 1997. Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 106:29-45. (Pubitemid 27383438)
22. Park CS, Kang JH, Chung WG, Yi HG, Pie JE, Park DK, Hines RN, McCarver DG, Cha YN. 2002. Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities. Pharmacogenetics 12:77-80. (Pubitemid 34112246)
23. Phillips IR, Francois AA, Shephard EA . (2007). The flavin-containing monooxygenases (FMOs): genetic variation and its consequences for the metabolism of therapeutic drugs. Curr Pharmacogenomics, 5, 292-313. (Pubitemid 350268214)
24. Poetsch M, Czerwinski M, Wingenfeld L, Vennemann M, Bajanowski T. 2010. A common FMO3 polymorphism may amplify the effect of nicotine exposure in sudden infant death syndrome (SIDS). Int J Legal Med 124:301-306.
25. Sachse C, Ruschen S, Dettling M, Schley J, Bauer S, Müller- Oerlinghausen B, Roots I, Brockmöller J. 1999. Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. Clin Pharmacol Ther 66:431-438. (Pubitemid 29494137)
26. Shimizu M, Yano H, Nagashima S, Murayama N, Zhang J, Cashman JR, Yamazaki H. 2007. Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities. Drug Metab Dispos 35:328-330. (Pubitemid 46333916)
27. Stephens M, Donnelly P. 2003. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162-1169. (Pubitemid 37414228)
28. Störmer E, Roots I, Brockmöller J. 2000. Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J Clin Pharmacol 50:553-561. (Pubitemid 32010780)
29. Yeung CK, Lang DH, Thummel KE, Rettie AE. 2000. Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab Dispos 28:1107-1111. (Pubitemid 30660367)
30. Zhou J, Shephard EA. 2006. Mutation, polymorphism and perspectives for the future of human flavin-containing monooxygenase 3. Mutat Res 612:165-171. (Pubitemid 43767092)